Search
forLearn
5 / 801 resultslearn Marine complex (freshly cosmetics)
learn mometasone furoate
learn Chestnut Phytocomplex
learn amodimethicone
Research
5 / 1000+ results
research Cosmeceuticals
Cosmeceuticals can improve skin health and appearance but need more research for safety and effectiveness.
research TFOS Lifestyle: Impact of cosmetics on the ocular surface
research In the eye of the beholder
Cosmeceuticals may have potential but their effectiveness and market success are still uncertain.
research Medical Technologies: Pharmaceutical Cosmetology, Cosmeceuticals – Opportunities and Limitations
Cosmeceuticals effectively treat skin issues but need better regulation and safety measures.
research Herbal Nanocosmeceuticals: The Ultimate Fusion of Science and Nature
Herbal nanocosmeceuticals are more effective and eco-friendly than traditional skincare products.
Community Join
5 / 1000+ resultscommunity Anyone tried this minoxidil product - Aqua based
Switching from alcohol-based to aqua-based minoxidil is discussed, specifically Cosmofix Minofix 5%. Users share experiences and opinions on the effectiveness and side effects of the switch.
community MinoxiBoost - SULT1A1 Enzyme booster journey
The user has tried topical Minoxidil and oral Minoxidil for beard and scalp hair growth with minimal results, and has been on Finasteride for 7 months with stabilized scalp hair but no facial hair improvement. They are considering using a SULT1A1 enzyme booster to enhance results and are questioning its effectiveness without concurrent topical Minoxidil application.
community Cosmo Pharma 2025 Investor Day Report
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
community Breezula Phase III 12-Month Data Released by Cosmo Pharma
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
community Cosmo Pharmaceutical (Breezula) fiscal results. Top Line Six month results expected early in the second half of this year.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.